Article
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
Blood cancer journal - 31 Jan 2020
Munshi Manit, Liu Xia, Chen Jiaji G, Xu Lian, Tsakmaklis Nickolas, Demos Maria G, Kofides Amanda, Guerrera Maria Luisa, Jimenez Cristina, Chan Gloria G, Hunter Zachary R, Palomba M Lia, Argyropoulos Kimon V, Meid Kirsten, Keezer Andrew, Gustine Joshua, Dubeau Toni, Castillo Jorge J, Patterson Christopher J, Wang Jinhua, Buhrlage Sara J, Gray Nathanael S, Treon Steven P, Yang Guang
Abstract excerpt
Activating MYD88 mutations promote pro-survival signaling through BTK and HCK, both targets of ibrutinib. Despite high response rates, complete responses to ibrutinib are lacking, and other MYD88 triggered pro-survival pathways may contribute to primary drug resistance. B-cell receptor (BCR) signaling has been observed in lymphomas driven by mutated MYD88, even without activating the BCR pathway mutations. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.